Spectris plc (“Spectris”) [LSE: SXS], a supplier of precision instrumentation and controls, has sold Concept Life Sciences, a leading integrated drug discovery, development and manufacturing organisation, to Limerston Capital LLP (“Limerston Capital”) in its new fund Limerston Capital Partners II, LP.

Founded in 1989, Concept Life Sciences is a leading global contract research organisation primarily serving the pharmaceutical and life sciences research and development market.  With a track record in project execution, delivering tangible value for customers’ IP generation, and stringent focus on quality, the company has around 300 employees and operates out of five facilities.

EC M&A acted as exclusive M&A advisor to Spectris on this transaction.